ZHEJIANG XINGUANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.06 CNY | +0.62% |
|
+0.62% | -21.18% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 351M 48.54M | Sales 2023 | 270M 37.35M | Capitalization | 2.65B 366M |
|---|---|---|---|---|---|
| Net income 2022 | 109M 15.05M | Net income 2023 | 64M 8.84M | EV / Sales 2022 | 5.03 x |
| Net cash position 2022 | 737M 102M | Net cash position 2023 | 699M 96.53M | EV / Sales 2023 | 7.22 x |
| P/E ratio 2022 |
23
x | P/E ratio 2023 |
41.4
x | Employees | 315 |
| Yield 2022 |
3.19% | Yield 2023 |
2.41% | Free-Float | 42.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.62% | ||
| 1 week | +0.62% | ||
| Current month | +2.59% | ||
| 1 month | +12.78% | ||
| 3 months | +14.26% | ||
| 6 months | -22.22% | ||
| Current year | -21.18% |
1 week
12.87
13.20
1 month
11.1713.61
Current year
8.4517.90
1 year
8.4519.88
3 years
8.4527.56
5 years
8.4530.48
10 years
7.6766.50
| Managers | Title | Age | Since |
|---|---|---|---|
Yue Jun Wang
CEO | Chief Executive Officer | 70 | 97-12-31 |
Bin Bin Xing
DFI | Director of Finance/CFO | 49 | 02-12-31 |
Zhu Ping Sun
CHM | Chairman | 61 | 98-11-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hu Gen Wang
BRD | Director/Board Member | 75 | 18-08-23 |
Yue Jun Wang
CEO | Chief Executive Officer | 70 | 97-12-31 |
Fu Yin Qiu
BRD | Director/Board Member | 62 | 00-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 13.06 | +0.62% | 1,540,300 |
| 24-05-17 | 12.98 | +0.46% | 1,396,900 |
| 24-05-16 | 12.92 | -0.77% | 1,886,900 |
| 24-05-15 | 13.02 | -1.51% | 1,836,600 |
| 24-05-14 | 13.22 | +1.85% | 2,600,000 |
End-of-day quote Shenzhen S.E., May 19, 2024
More quotes
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in development, manufacture and sales of Chinese patent medicines, chemical medicines and health foods. The main products of the Company are cardiovascular and cerebrovascular diseases medicine as well as traumatic disease medicine. Its other products include the drugs used in respiratory systems, digestive systems, urinary systems, paediatric diseases and immune systems. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.18% | 288M | |
| +21.63% | 44.12B | |
| +23.26% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.61B | |
| +60.18% | 13.34B | |
| -8.64% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +15.65% | 5.63B |
- Stock Market
- Equities
- 300519 Stock
